Burzynski Research (BZYR) 0.0700 $BZYR Burzynski

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Burzynski Research (BZYR) 0.0700 $BZYR

Burzynski Research Institute, Inc. Announces the Launch of a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma
BusinessWire - Thu Apr 14, 10:32AM CDT
Burzynski Research Institute, Inc. (BRI) announced today that it has begun patient enrollment into an FDA-reviewed and IRB-approved, open-label, single-arm phase 2 study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). Study subjects will be placed in one of five treatment groups based on their age and whether or not they have received prior treatment for DIPG. The primary study endpoint is a decrease in the size of the tumor, either a partial response (greater-than or equal to 50% decrease in the size of the tumor) or a complete response (disappearance of the tumor).

Anaplastic Astrocytoma Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/mp9hzf/anaplastic) has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Anaplastic Astrocytoma Overview - Therapeutics Development - Pipeline Products for Anaplastic Astrocytoma - Overview - Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis - Anaplastic Astrocytoma - Therapeutics under Development by Companies - Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes - Anaplastic Astrocytoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Anaplastic Astrocytoma - Products under Development by Companies - Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes - Anaplastic Astrocytoma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Amgen Inc. - Axelar AB - Boehringer Ingelheim GmbH - Burzynski Research Institute, Inc. - Cavion LLC - Celldex Therapeutics, Inc. - e-Therapeutics Plc - Eli Lilly and Company - Millennium Pharmaceuticals, Inc. - Novartis AG - Orbus Therapeutics, Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/mp9hzf/anaplastic
ADRO: 13.39 (-0.38), PFE: 34.82 (+0.05), CLDX: 3.49 (+0.02), AMGN: 171.97 (+1.74), LLY: 78.24 (+0.23), NVS: 79.31 (-0.24)

A Look at Four Brain Cancer Companies for 2016
ACCESSWIRE - Mon Jan 04, 10:34AM CST
NEW YORK, NY / ACCESSWIRE / January 4, 2016 / BioTechstocks.com - Brain tumors are among the most difficult to treat cancers in the oncology space. Their tendency for late stage diagnosis, and the difficulty associated with surgical treatment, translates to a higher than 65% mortality rate in the US, defined as the percentage of patients that die within five years of diagnosis. Choosing to pursue brain cancer treatment is risky for a company precisely because it is so hard to treat. That's why new approaches are being pursued mainly by smaller companies trying to make an impact with bigger risk-taking. Here are four candidates from these smaller firms to keep in eye in 2016.
DMPI: 6.85 (-0.03), VBLT: 4.07 (-0.17), IMUC: 0.12 (unch)

Burzynski Research Institute, Inc. Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1
BusinessWire - Mon Dec 07, 12:42PM CST
Burzynski Research Institute, Inc. (BRI) announced today the publication of "A Phase II Study of Antineoplastons A10 and AS2-1 (ANP) in Adult Patients with Primary Brain Tumors - Final Report (Protocol BT-09)". This single arm, two stage, phase II clinical trial, was designed to treat adults with different types of primary brain tumors that were not curable by standard therapy. Fourteen of 40 patients treated (35%) had an anaplastic glioma (AG), of which 12 (86%) had an anaplastic astrocytoma (AA), a grade 3 tumor with a poor prognosis. In BT-09, the objective response rate in AA patients was 42% while the median progression-free survival was 5.4 months. The median overall survival (OS) for AA patients was 25.4 months with the OS at 6 months, 1 year, and 2 years being 83%, 58%, and 50% respectively, which compares favorably with current standard treatment. ANP was well-tolerated with reversible grade 3 and 4 toxicity in 35% of all 40 patients treated. After a review of BRI's Investigator Brochure and annual reports, which documented outcomes for all AGs treated with ANP in phase II clinical trials, the FDA, in personal correspondence with BRI, advised an end-of-phase II meeting "for grade 3 AGs, specifically AA, anaplastic oligodendroglioma, and mixed oligoastrocytoma [OR rate of 20% (95% CI: 12, 31)]", indicating that ANP exhibited sufficient clinical activity in these tumors to justify further development.

Burzynski Research Institute, Inc. Announces Publications Documenting Long-term Survival in Malignant Brain Tumors Following Antineoplaston Therapy
PR Newswire - Mon Oct 26, 5:03PM CDT
Burzynski Research Institute, Inc. (BRI) announced today the publication of two articles in the peer-reviewed literature that document long-term survival in patients with a high-grade glioma (HGG) following Antineoplaston therapy (ANP). Following standard therapy, HGGs have a very poor prognosis. A meta-analysis of 575 HGG studies involving 42,332 patients showed median overall survival ranging from 9.89 to 15.45 months depending on the type of adjuvant chemotherapy employed [Leonard A, et al. J. Neuro Oncol 2012 Jun; 14(Suppl 1): 156-168. doi: 10.1093/neuonc/nos12].

Gliosarcoma Pipeline Review H1 2015 - Analysis of 7 Companies & 11 Drug Profiles
M2 - Tue Jul 28, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mmkt6/gliosarcoma) has announced the addition of the "Gliosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Burzynski Research Institute, Inc. - Celgene Corporation - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Sanofi Drug Profiles - alisertib - Antineoplaston Therapy - CC-122 - DNX-2401 - indoximod - lonafarnib - Oncolytic Virus to Target IL-12 for Oncology - plerixafor - rilotumumab - SGT-53 - Stem Cell Therapy for Glioma For more information visit http://www.researchandmarkets.com/research/5m...liosarcoma
MRK: 62.85 (+0.53), NLNK: 10.05 (+0.11), AMGN: 171.97 (+1.74), CELGZ: 1.13 (-0.05)

Anaplastic Astrocytoma - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv742d/anaplastic) has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amgen Inc. - Boehringer Ingelheim GmbH - Burzynski Research Institute, Inc. - Cavion LLC - e-Therapeutics plc - Eli Lilly and Company - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncovir, Inc. - Orbus Therapeutics, Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/cv742d/anaplastic
PFE: 34.82 (+0.05), AMGN: 171.97 (+1.74), LLY: 78.24 (+0.23), NVS: 79.31 (-0.24)

Anaplastic Astrocytoma Therapeutic Products and Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 18, 8:30PM CDT
The report "Anaplastic Astrocytoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Anaplastic Astrocytoma with 33 market data tables and 14 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/anaplastic-a...eport.html .
PFE: 34.82 (+0.05), LLY: 78.24 (+0.23), NVS: 79.31 (-0.24)

Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma
BusinessWire - Thu Jun 18, 2:09PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.

Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Patients with Non-Diffuse Intrinsic Pontine Glioma
BusinessWire - Thu Apr 16, 5:46PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain and brainstem tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.

Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Newly-Diagnosed Anaplastic Astrocytoma
BusinessWire - Tue Mar 31, 4:25PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with rare brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.

Burzynski Research Institute, Inc. Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver
PR Newswire - Thu Mar 26, 5:51PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver.

Burzynski Research Institute awarded US FDA's approval to begin new clinical trial in Diffuse Intrinsic Brainstem Glioma
M2 - Mon Oct 27, 6:20AM CDT
Biopharmaceutical company Burzynski Research Institute (Other OTC:BZYR) revealed on Friday that it has received approval from the US Food and Drug Administration (FDA) to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > three months of age with a diffuse intrinsic brainstem glioma (DIPG), the most common brainstem tumor in children.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 98

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 50

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading

Top 5 Most Recently Viewed Articles

Ross Gerber Expresses Optimism for Meta's Phone-Free Future

Updated Category News Views 242

Ross Gerber Praises Meta's Smart Glasses Technology Over the weekend, investor Ross Gerber expressed his admiration for Meta Platforms, Inc. (NASDAQ: META) smart glasses, affirming their potential to transform our relationship with technology. Gerber noted that this innovative eyewear gives him hope for a day when he might no longer rely on his smartphone. Smart Glasses:...

Continue Reading
Organ-on-a-Chip Market Insights and Future Projections

Updated Category News Views 118

Understanding the Organ-on-a-Chip Market Growth As technology evolves, the quest for more accurate and human-relevant drug testing models takes center stage. The Organ-on-a-Chip (OOC) market has emerged as a revolutionary force, previously valued at around USD 117.67 million, and now set to skyrocket to approximately USD 1.64 billion by 2032. This innovative approach is...

Continue Reading
Discovering Blue Light Cystoscopy Benefits in Bladder Cancer

Updated Category News Views 240

New Insights on Blue Light Cystoscopy and Bladder Cancer Photocure ASA, known as the Bladder Cancer Company, has made significant advancements in bladder cancer management with the recent study titled "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO Study." This research published in JU Open Plus provides compelling evidence...

Continue Reading
BioCryst's Bold Move: Astria Therapeutics Acquisition Insights

Updated Category News Views 211

BioCryst Enhances HAE Portfolio with Astria Acquisition BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has made a significant announcement regarding its acquisition of Astria Therapeutics, Inc. (NASDAQ: ATXS). This strategic move will strengthen BioCryst's position in the hereditary angioedema (HAE) market, as they plan to integrate Astria's promising therapies and...

Continue Reading
Milestone Scientific Reaches New Height with Strong Growth

Updated Category News Views 361

Milestone Scientific Achieves 52-Week High Milestone Scientific Inc. (NYSE: MLSS) has reached a significant milestone with its stock trading at $1.28, marking a 52-week high. This impressive achievement highlights the company's robust annual growth and increased investor confidence. As a result, the current market capitalization has reached approximately $97.37 million,...

Continue Reading